Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743465 · ClinicalTrials.gov registry record
A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
A clinical trial of Leukemia, sponsored by Takeda.
- Completed
- Registry status
- 1,769
- Enrollment target
- 1
- Study location
NCT05743465 is a study of Leukemia that has completed, run by Takeda. The registered enrollment target is 1,769 participants, above the 479-participant average among 233 other Leukemia trials with a reported enrollment target (269% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05743465, a study of Leukemia, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 1,769 participants
- Enrollment target
- 1
- Study location
Study Summary
The aims of this study are to learn out about treatment information (including amongst others treatment patterns, safety, development of a participant's condition) ponatinib, bosutinib, imatinib, dasatinib and nilotinib using already available data. No new data will be collected from participants as part of this study and no study medicines will be provided in this study.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
Massachusetts
- Takeda - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,769 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2022-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05743465
The ClinicalTrials.gov registry entry for NCT05743465 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,769 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 479-participant average among 233 other Leukemia trials with a reported enrollment target (269% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT05743465 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05743465 about?
NCT05743465 is a clinical study titled "A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia". The aims of this study are to learn out about treatment information (including amongst others treatment patterns, safety, development of a participant's condition) ponatinib, bosutinib, imatinib, dasatinib and nilotinib using already available data. No new data will be collected from participants as...
What is the current status of trial NCT05743465?
This trial is currently completed. The enrollment target is 1,769 participants. The study started on 2021-10-06. Estimated completion is 2022-11-30.
What conditions does trial NCT05743465 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT05743465?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05743465?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05743465 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.